Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
This document is hosted externally.
Unless the owner has removed it from the web, you can access the full document via its original URL:
https://investors.biontech.de/node/8476/pdfUnless the owner has removed it from the web, you can access the full document via its original URL:
See similar contracts (3)
Alternatively, you can try searching for similar contracts: